Altimmune Faces Class Action Lawsuit Over Stock Plunge After Trial Results
A class action lawsuit has been initiated against Altimmune, Inc. on behalf of investors who suffered losses due to alleged securities fraud. The suit, filed between August 10, 2023 and June 25, 2025, follows a significant drop in Altimmune's stock price after disappointing trial results.
On June 25, 2025, Altimmune announced that its IMPACT Phase 2b MASH trial of Pemvidutide did not meet its primary endpoint of fibrosis reduction. This news sent the company's stock price plummeting by 53.2% in a single day. Investors affected by this sudden drop may have until October 6, 2025 to request the Court to appoint them as lead plaintiff in the lawsuit.
Levi & Korsinsky, LLP is currently notifying these investors and seeking to recover their losses. The lead attorney or prosecutor in this case is not publicly known at this time.
The class action lawsuit against Altimmune, Inc. is ongoing, with investors having until October 6, 2025 to potentially join as lead plaintiffs. The firm Levi & Korsinsky, LLP is actively representing affected investors, aiming to secure compensation for their losses.
Read also:
- HLC Approves ₹4,645.60 Crore for Flood Recovery and Wetland Rejuvenation in Nine States
- Crooked House Pub's Demolition: Council Orders Rebuild, Debate on Historic Building Protections
- Shaping India's Economic Progression: Readying the Financial System for Tomorrow
- Ethiopia's Grand Dam: 15,000 Lives Lost, Water Concerns Unresolved
